Drug Profile
VP 50406
Alternative Names: HCI 436Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator ViroPharma
- Class Antivirals
- Mechanism of Action RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 14 Nov 2001 Discontinued-II for Hepatitis C in United Kingdom (Unknown route)
- 03 Mar 2000 Phase-I clinical trials for Hepatitis C in United Kingdom (Unknown route)